Non-canonical Hh signaling in cancer—Current understanding and future directions

Dongsheng Gu, Jingwu Xie

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

As a major regulatory pathway for embryonic development and tissue patterning, hedgehog signaling is not active in most adult tissues, but is reactivated in a number of human cancer types. A major milestone in hedgehog signaling in cancer is the Food and Drug Administration (FDA) approval of a smoothened inhibitor Vismodegib for treatment of basal cell carcinomas. Vismodegib can block ligand-mediated hedgehog signaling, but numerous additional clinical trials have failed to show significant improvements in cancer patients. Amounting evidence indicate that ligand-independent hedgehog signaling plays an essential role in cancer. Ligand-independent hedgehog signaling, also named non-canonical hedgehog signaling, generally is not sensitive to smoothened inhibitors. What we know about non-canonical hedgehog signaling in cancer, and how should we prevent its activation? In this review, we will summarize recent development of non-canonical hedgehog signaling in cancer, and will discuss potential ways to prevent this type of hedgehog signaling.

Original languageEnglish (US)
Pages (from-to)1684-1698
Number of pages15
JournalCancers
Volume7
Issue number3
DOIs
StatePublished - Aug 27 2015

Fingerprint

HhAntag691
Neoplasms
Ligands
Drug Approval
Basal Cell Carcinoma
United States Food and Drug Administration
Embryonic Development
Direction compound
Clinical Trials
Therapeutics

Keywords

  • Gli
  • Hedgehog
  • Non-canonical
  • Smoothened

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Non-canonical Hh signaling in cancer—Current understanding and future directions. / Gu, Dongsheng; Xie, Jingwu.

In: Cancers, Vol. 7, No. 3, 27.08.2015, p. 1684-1698.

Research output: Contribution to journalReview article

@article{2ebfd87638304ab9bc7afdb258cd98f8,
title = "Non-canonical Hh signaling in cancer—Current understanding and future directions",
abstract = "As a major regulatory pathway for embryonic development and tissue patterning, hedgehog signaling is not active in most adult tissues, but is reactivated in a number of human cancer types. A major milestone in hedgehog signaling in cancer is the Food and Drug Administration (FDA) approval of a smoothened inhibitor Vismodegib for treatment of basal cell carcinomas. Vismodegib can block ligand-mediated hedgehog signaling, but numerous additional clinical trials have failed to show significant improvements in cancer patients. Amounting evidence indicate that ligand-independent hedgehog signaling plays an essential role in cancer. Ligand-independent hedgehog signaling, also named non-canonical hedgehog signaling, generally is not sensitive to smoothened inhibitors. What we know about non-canonical hedgehog signaling in cancer, and how should we prevent its activation? In this review, we will summarize recent development of non-canonical hedgehog signaling in cancer, and will discuss potential ways to prevent this type of hedgehog signaling.",
keywords = "Gli, Hedgehog, Non-canonical, Smoothened",
author = "Dongsheng Gu and Jingwu Xie",
year = "2015",
month = "8",
day = "27",
doi = "10.3390/cancers7030857",
language = "English (US)",
volume = "7",
pages = "1684--1698",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "3",

}

TY - JOUR

T1 - Non-canonical Hh signaling in cancer—Current understanding and future directions

AU - Gu, Dongsheng

AU - Xie, Jingwu

PY - 2015/8/27

Y1 - 2015/8/27

N2 - As a major regulatory pathway for embryonic development and tissue patterning, hedgehog signaling is not active in most adult tissues, but is reactivated in a number of human cancer types. A major milestone in hedgehog signaling in cancer is the Food and Drug Administration (FDA) approval of a smoothened inhibitor Vismodegib for treatment of basal cell carcinomas. Vismodegib can block ligand-mediated hedgehog signaling, but numerous additional clinical trials have failed to show significant improvements in cancer patients. Amounting evidence indicate that ligand-independent hedgehog signaling plays an essential role in cancer. Ligand-independent hedgehog signaling, also named non-canonical hedgehog signaling, generally is not sensitive to smoothened inhibitors. What we know about non-canonical hedgehog signaling in cancer, and how should we prevent its activation? In this review, we will summarize recent development of non-canonical hedgehog signaling in cancer, and will discuss potential ways to prevent this type of hedgehog signaling.

AB - As a major regulatory pathway for embryonic development and tissue patterning, hedgehog signaling is not active in most adult tissues, but is reactivated in a number of human cancer types. A major milestone in hedgehog signaling in cancer is the Food and Drug Administration (FDA) approval of a smoothened inhibitor Vismodegib for treatment of basal cell carcinomas. Vismodegib can block ligand-mediated hedgehog signaling, but numerous additional clinical trials have failed to show significant improvements in cancer patients. Amounting evidence indicate that ligand-independent hedgehog signaling plays an essential role in cancer. Ligand-independent hedgehog signaling, also named non-canonical hedgehog signaling, generally is not sensitive to smoothened inhibitors. What we know about non-canonical hedgehog signaling in cancer, and how should we prevent its activation? In this review, we will summarize recent development of non-canonical hedgehog signaling in cancer, and will discuss potential ways to prevent this type of hedgehog signaling.

KW - Gli

KW - Hedgehog

KW - Non-canonical

KW - Smoothened

UR - http://www.scopus.com/inward/record.url?scp=84941005213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941005213&partnerID=8YFLogxK

U2 - 10.3390/cancers7030857

DO - 10.3390/cancers7030857

M3 - Review article

AN - SCOPUS:84941005213

VL - 7

SP - 1684

EP - 1698

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 3

ER -